Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.
Does apixaban prevent stroke or systemic embolism in patients with atrial fibrillation?
In patients with atrial fibrillation, apixaban is superior to warfarin for preventing stroke or systemic embolism, with the added benefits of less bleeding and lower mortality.
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).
Granger et al. (2011) studied this question. Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: